# Brazil’s Anvisa Expands Medical Cannabis Rules, Allows Compounding Pharmacies

*Regulatory overhaul broadens administration routes, eases access to THC therapies and marks a milestone for patient treatment.*

- Published: 2026-01-28
- Updated: 2026-01-29
- Section: Insights
- Tags: Anvisa, Brazil health policy, Brazil healthcare regulation, cannabidiol, compounding pharmacies, medical cannabis, pharmaceutical regulation, public health, THC
- URL: https://brazilstockguide.com/insights/brazil-anvisa-medical-cannabis-regulation/

![](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2026/01/Cannabis.jpg?fit=1024%2C683&ssl=1)

**By Brazil Stock Guide –** Brazil’s health regulator **Anvisa** approved a resolution on Wednesday that significantly expands the country’s framework for **medical cannabis therapies**, allowing compounded **cannabidiol** products to be sold by **compounding pharmacies**, broadening permitted **routes of administration** and easing restrictions on medicines with higher **THC concentrations**. The agency said the changes represent an important regulatory advance for patients with **severe and debilitating conditions**.

Under the new rules, **cannabis-based medicines** will be permitted for **buccal, sublingual and dermatological use**. Until now, approved products were largely limited to **oral and inhaled administration**. The decision was grounded in scientific evidence reviewed during Anvisa’s **Regulatory Impact Analysis**, which assessed **clinical effectiveness**, **safety** and **public-health risks**.

**Broader therapeutic routes**
Anvisa said the **dermatological route** was included because it is considered **lower risk**, as it limits **systemic exposure to cannabinoids**. **Buccal and sublingual routes** were approved for bypassing **first-pass liver metabolism**, which can improve **bioavailability** and offer more predictable **therapeutic effects**. The agency also introduced a **technical adjustment** by formally replacing the term **“nasal route”** with **“inhalation route,”** aligning regulatory language with its existing standards.

**Eased access to THC therapies**
One of the most consequential changes involves medicines with **THC concentrations above 0.2%**. Previously restricted to patients in **palliative care** or with **irreversible or terminal conditions**, such products may now also be prescribed to patients suffering from **severe debilitating diseases**. The update substantially broadens the **therapeutic scope** of THC-based treatments, while maintaining **medical oversight** and **regulatory controls**, Anvisa said.

**Compounding and patient access**
The resolution also authorizes the **compounding of cannabis-based medicines** by licensed **compounding pharmacies**, provided prescriptions are **individualized**. The measure is expected to improve **access**, **reduce costs** and allow formulations to be better **tailored to patients’ clinical needs**.

**Controlled communication**
While keeping tight limits on **commercial communication**, Anvisa introduced a narrow relaxation. **Advertising of cannabis-based products**, previously banned, will now be allowed exclusively for **prescribing healthcare professionals**. Any such communication must be limited to **labeling information** and **official package leaflets** approved by the regulator.

Anvisa stressed that the resolution does **not change Brazil’s prohibition of recreational cannabis use**. Cannabis and its derivatives remain legal **only for medical purposes**, under **prescription** and within the country’s existing **sanitary and regulatory framework**, reinforcing oversight of a rapidly evolving market.

---

Source: Brazil Stock Guide, https://brazilstockguide.com/insights/brazil-anvisa-medical-cannabis-regulation/
